Dr. Rebecca Windsor on Stem Cell Therapy Advances in FCGS

In a recent episode of All Cats Considered, Gallant’s Director of Veterinary Affairs, Dr. Rebecca Windsor, joined host Dr. Cathy Lund to discuss the future of regenerative medicine and its impact on one of feline medicine’s most challenging conditions: chronic gingivostomatitis (FCGS).

Drawing on more than two decades as a board-certified veterinary neurologist, Dr. Windsor shares how her clinical experience with complex inflammatory and immune-mediated diseases ultimately led her to Gallant—and to the forefront of developing FDA-regulated stem cell therapies. She highlights the promising results seen in investigational studies for FCGS, where stem cells act as potent immunomodulators capable of addressing the root causes of disease rather than simply managing pain and inflammation.

From All Cats Considered
Episode 311: Dr. Rebecca Windsor on Stem Cell Therapy Advances in FCGS

Her conversation underscores an important message for veterinarians: regenerative medicine represents a fundamentally new category of care. As she explains on the podcast, stem cell therapies have the potential to restore health at the source—offering new options for cats who have exhausted traditional treatments like full-mouth extractions and chronic medical management.

At Gallant, that vision is becoming reality through investigational, ready-to-use stem cell therapies now in development for FCGS and other conditions where inflammation and immune dysregulation play a central role.

For Dr. Windsor, being featured on All Cats Considered was an opportunity to illuminate the science, the promise, and the practical future of stem cell therapy in everyday veterinary practice—and to help ensure clinicians have access to safe, effective, and science-driven tools that elevate patient care.